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Abstract 34	
Background: Recent studies suggest that cortical lesions in multiple sclerosis (MS) 35	
substantially contribute to clinical disease severity. The present study aimed at 36	
investigating clinical, neuroanatomical, and cognitive correlates of these cortical 37	
lesions with a novel approach, i.e. by comparing two samples of relapsing-remitting 38	
multiple sclerosis (RRMS) patients, one group with and the other without cortical 39	
lesions. 40	
Methods: High-resolution structural MRI was acquired from 42 RRMS patients and 41	
43 controls (HC). The patient group was dichotomized based on the presence versus 42	
absence of DIR-hyperintense cortex-involving lesions, resulting in a cortical lesion 43	
group (CL, n=32) and a non-cortical lesion group (nCL, n =10). Cognitive 44	
functioning was assessed in all participants with a comprehensive neuropsychological 45	
battery, covering mnestic, executive, and attentional functions. 46	
Results: Highest densities of cortical lesions in the CL group were observed in the 47	
bilateral parahippocampal gyrus. Relative to HC, patients with cortical lesions - but 48	
not those without - showed significant global cortical thinning and mnestic deficits. 49	
The two patient groups did not differ from each other regarding demographic and 50	
basic disease characteristics such as EDSS scores.  51	
Conclusion: The appearance of cortical lesions in MS patients is associated with 52	
cortical thinning as well as mnestic deficits, which might be key characteristics of a 53	
'cortically dominant' MS subtype. 54	
 55	
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Background 59	
Traditionally, multiple sclerosis (MS) is considered as an autoimmune inflammatory 60	
disorder [1], predominantly affecting the white matter of the central nervous system 61	
[2]. This view is based on the high sensitivity of conventional MRI sequences in the 62	
detection of white matter abnormalities in MS patients. Nevertheless, histopathologic 63	
analyses of demyelinated foci in the cerebral cortex of patients with MS - dating back 64	
to the beginning of the 20th century [3] -  gave first evidence for cortical involvement 65	
in MS. In the early 1960s, Brownell and Hughes described that 26% of the MS lesions 66	
affected the gray matter [4]. However, the classical view of MS as a pure white matter 67	
pathology has not been overcome until the beginning of the 21st century. Due to the 68	
introduction of more sensitive imaging techniques such as double inversion recovery 69	
(DIR), gray matter involvement of the MS pathology is now well established [5,6]. 70	
By suppressing the signals form the cerebrospinal fluid and white matter, DIR 71	
sequences have a higher sensitivity compared to conventional MR sequences [4] and 72	
thus, have made a major contribution in detecting focal cortical lesions in MS. 73	
Although a recent study has shown that DIR can detect only a minority of cortical 74	
lesions in MS, the same study has also shown a significant correlation between the 75	
number of DIR-hyperintense cortical lesions on the one hand and the total number of 76	
cortical lesions in post-mortem histopathologic analysis on the other hand [7]. 77	
Moreover, DIR is currently considered the best wide-scale application pulse sequence 78	
for cortical lesion detection and offers high sensitivity, specificity and accuracy for 79	
the detection of gray matter lesions [8]. 80	
Multiple sclerosis is associated with a variety of symptoms that are responsible for 81	
functional impairment in affected patients. Besides physical disability, cognitive 82	
deficits – which were firstly described in the second half of the 19th century [9] – are 83	
found in up to 70% of patients with multiple sclerosis at both the earlier and later 84	
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stages of the disease [10]. MS-related cognitive impairment can affect various aspects 85	
of cognition. Processing speed and episodic memory seem most commonly affected 86	
[11]. However, MS patients often exhibit significant deficits in executive functions 87	
too [12,13].  88	
The extended focus in MS research including gray matter pathology had important 89	
consequences for the study of the neural correlates of MS symptoms. In recent years, 90	
the contribution of DIR-hyperintense cortical lesions to functional loss is particularly 91	
highlighted. Cross-sectional and longitudinal studies have shown correlations between 92	
the number and/or volume of cortical lesions and cognitive [14,15] or physical [16] 93	
impairment. Regional associations are also described, for instance between an 94	
accumulation of cortical lesions in mesio-temporal areas and impairments in episodic 95	
memory [12,17]. 96	
However, these studies are not without limitations. For example, detailed cognitive 97	
investigation [14] or DIR sequences were lacking [15]. Here we try to overcome these 98	
shortcomings and apply a novel methodological approach to investigate the clinical 99	
relevance of cortical lesions in MS, i.e. by dichotomizing patients based on the 100	
presence or absence of cortical lesions. The resulting two subgroups were compared 101	
with regard to demography, cognition, fatigue, affective mood state, and several other 102	
established MRI markers of disease severity, for example T2 lesion load, third 103	
ventricle width, and global cortical thinning.  104	
 105	
Methods 106	
Participants 107	
Forty-two patients with a diagnosis of relapsing-remitting multiple sclerosis (RRMS) 108	
according to the McDonald 2010 criteria [18] were recruited at the Multiple Sclerosis 109	
Centre of the University Hospital of Zurich. Patients with at least one DIR-110	
	 5
hyperintense cortex-involving lesion were assigned to the cortical lesion group (CL 111	
group, n = 32), the remaining patients formed the non-cortical lesion group (nCL 112	
group, n = 10). All patients received immunomodulatory treatment - 30 with 113	
natalizumab, seven with beta-interferons, three with fingolimod, one with glatiramer 114	
acetat and one with dimethylfumarate. Exclusion criteria were a relapse or steroid-115	
treatment during the last two months, current or past neurological disorders in 116	
addition to multiple sclerosis, and psychiatric disorders apart from MS-related 117	
depressive mood state. Moreover, none of the patients was affected by severe visual 118	
deficits or upper limb sensorimotor impairment that could hinder cognitive test 119	
performance. Furthermore, 43 age-, gender-, handedness- and education-matched 120	
healthy control persons (HC) without previous or present history of neurological or 121	
psychiatric diseases were included. Controls received financial compensation for their 122	
attendance.  123	
 124	
MRI data acquisition  125	
The MR scan was performed within one month of the neurological and 126	
neuropsychological examinations. All images were acquired using a 1.5-T scanner 127	
(Siemens Magnetom AvantoTM) equipped with a SQ-engine gradient (45m/T/m @ 128	
200 T/m/s), using a dedicated 32-channel head coil. No hardware upgrades of the 129	
scanner occurred during the study period. The following sequences were performed in 130	
all subjects: (1) 3D Double Inversion Recovery (DIR) (voxel size = 1.5 x 1.5 x 1.5 131	
mm, slice thickness = 1.5 mm, repetition time = 7500ms, echo time = 308ms, 132	
inversion timing 1 = 3000 ms, inversion timing 2 = 450 ms); (2) 3D T1-weighted 133	
MPRAGE (voxel size = 1 x 1 x 1 mm, slice thickness = 1 mm, repetition time = 2420 134	
ms, echo time = 4.18 ms), and (3) 3D FLAIR (voxel size = 0.9 x 0.9 x 2.0 mm, slice 135	
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thickness = 2 mm, repetition time = 5000 ms, echo time = 342 ms, inversion time = 136	
1800ms).  137	
 138	
MRI post-processing and statistical analysis 139	
The classification of cortical lesions was conducted according to the consensus 140	
recommendations of Geurts and colleagues [19]. Consequently, cortical lesions were 141	
defined as those lesions appearing hyperintense on DIR images compared to 142	
surrounding normal-appearing gray matter, entirely or partly located in the cortical 143	
gray matter and occupying at least three voxels. Juxtacortical lesions (lesions not 144	
entering, but neighboring the cortical mantle) were not scored. DIR-hyperintense 145	
lesions were identified and manually delineated with MRIcron 146	
(http://sph.sc.edu/comd/rorden/mricron), which was further used to measure total 147	
cortical lesion volume. An experienced rater, supervised by a neuroradiologist, 148	
assessed all images. The same procedure was applied to FLAIR images in order to 149	
identify FLAIR-hyperintense lesions. We used Statistical Parametric Mapping 150	
(SPM8, http://www.fil.ion.ucl.ac.uk/spm/) to co-register and normalize the individual 151	
lesion maps to MNI (Montreal Neurological Institute) standard space according to the 152	
normalization procedure proposed by Crinion and colleagues [20]. Normalized binary 153	
lesion maps were than plotted with MRIcron onto a T1-weighted MNI template brain 154	
to create lesion overlap plots. Central brain atrophy was examined by measuring the 155	
width of the third ventricle (TVW) according to the procedure proposed by Benedict 156	
and colleagues [21]. Brain parenchymal fraction (BPF), calculated as the ratio of 157	
brain parenchymal tissue volume to the total intracranial volume, was used as a 158	
measurement of whole-brain atrophy. The calculation was performed with Jim 159	
software (Xinapse Systems Ltd., Northants (UK); http://www.xinapse.com). Global 160	
cortical thickness evaluation was performed with the semi-automated Freesurfer 161	
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image analysis suite based on MPRAGE images, which is documented and freely 162	
available online (http://surfer.nmr.mgh.harvward.edu). Further information and 163	
technical details of these procedures are described in prior publications [22,23]. To 164	
detect possible misclassifications of white and gray matter due to multiple sclerosis 165	
lesions, all images were visually inspected after the white/gray matter segmentation. 166	
In two patients, a semi-automated correction of topological defects was required. We 167	
used the manual procedure of control points, which is implemented in the Freesurfer 168	
software package. No further lesion masking was needed in order to obtain accurate 169	
reconstructions of the pial and the white matter surfaces.  170	
 171	
Clinical and neuropsychological assessment  172	
All patients underwent neurological status examination, including the Expanded 173	
Disability Status Scale (EDSS). Cognitive functions were assessed with a 174	
comprehensive battery of validated and standardized neuropsychological tests. To 175	
minimize the issue of multiple statistical testing, composite index scores were 176	
computed for mnestic, executive and attentional functions by averaging z-scores for 177	
all subtests of the corresponding function [24]. An overview of the indices is shown in 178	
Additional File 1. The mnestic index score was derived from the delayed free recall 179	
and recognition of a 15-item word list [25] as well as the delayed free recall and 180	
recognition of a previously copied complex geometric figure [26]. Phonemic-verbal 181	
[27] and figural fluency [28], response inhibition [29] and cognitive flexibility [29] 182	
formed the executive index. The attentional index was based on processing speed 183	
during color naming [29] as well as on reaction times from tasks measuring alertness 184	
and selective attention [30]. Moreover, participants had to complete a German version 185	
[31] of the CES-D Depression questionnaire [32] and the Würzburg Fatigue Inventory 186	
(WEIMuS) [33] to self-rate depressive symptoms as well as fatigue during the last 187	
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week. Similar to other studies [34], cognitive reserve was examined with passive 188	
vocabulary knowledge (multiple choice word test) [35]. 189	
 190	
Statistical analysis 191	
Statistical analyses were performed with SPSS (IBM, Chicago, USA, Version, 21.0, 192	
http://spss.com). Unless otherwise stated, a p-level below 5% was considered 193	
statistically significant. Assumptions for normality were tested for all continuous data 194	
with Kolmogorov-Smirnov tests. In case of normally distributed variables, a 195	
multivariate ANOVA was used to compare groups. Bonferroni correction was applied 196	
for post-hoc analyses. When variables were not normally distributed, non-parametric 197	
tests were applied (Mann-Whitney U, Kruskal-Wallis).  198	
 199	
Results 200	
Demographic and clinical variables 201	
Demographic and clinical characteristics of the three groups are reported in Table 1. 202	
No between-group differences were found with regard to age, education, cognitive 203	
reserve and gender. Furthermore, EDSS, age at diagnosis, and disease duration did 204	
not differ significantly between CL and nCL patients. 205	
 206	
MRI markers 207	
We detected cortical lesions in 32 of 42 patients (76%). The highest occurrence of 208	
cortical lesions was found bilaterally in the parahippocampal gyrus (Fig. 1). Twenty-209	
five percent of the CL patients showed at least one cortical lesion in this region. An 210	
overview of the atrophy measurements in the three groups is given in Fig. 2. The three 211	
groups differed significantly from one another with regard to BPF (F(2) = 22.4, p < 212	
0.001), TVW (H(2) = 20.9, p < 0.001) and global cortical thickness (F(2) = 11.6, p < 213	
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0.001). Bonferroni-corrected post-hoc analyses revealed a reduction of BPF in CL 214	
patients relative to HC (p < 0.001) as well as an enlarged TVW (p < 0.001). In 215	
contrast, the BPF and TVW values of nCL patients did not differ from those of CL 216	
patients or controls. Furthermore, Bonferroni-corrected post-hoc analyses revealed a 217	
reduction of global cortical thickness in CL patients compared to HC (p <  0.001) and 218	
nCL (p = 0.029) patients, while HC and nCL patients did not differ from one another. 219	
Regarding the FLAIR-hyperintense lesion volume, no significant difference (p = 220	
0.064) was observed between the two patient groups. 221	
 222	
Cognitive test results, fatigue and depression questionnaires 223	
The attentional index did not differ significantly between the three groups (F(2) = 224	
1.207, p = 0.304). In contrast, a group effect was observed for the executive index 225	
(H(2) = 22.476, p < 0.001). Both patient groups showed executive dysfunction 226	
compared to HC (CL vs. HC: Z(2) = -4.272, p < 0.001; nCL vs. HC: Z(2) = -3.197, p 227	
< 0.001), but did not differ from one another (Z(2) = -0.251, p = 0.805). Furthermore, 228	
there was a main group effect for mnestic functions (F(2) = 7.667, p < 0.001). 229	
Bonferroni-corrected post-hoc analyses revealed that the CL group performed 230	
significantly worse in memory tests than both nCL patients (p = 0.031) and HC (p < 231	
0.001), whereas nCL patients did not differ from HC in this regard. Fig. 3 depicts the 232	
three cognitive indices and corresponding differences between groups. According to 233	
supplemental analyses (summarized in Additional File 2) of the individual tests 234	
pooled in the memory index, differences between the two patient groups were most 235	
strongly pronounced in figural recognition. No main group effect was observed for 236	
depression (H(2) = 5.634, p = 0.060). However, both patient groups showed 237	
significantly enhanced fatigue scores compared to HC (CL vs. HC: Z(2) = -2.319, p = 238	
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0.020; nCL vs. HC: Z(2) = -2.102, p = 0.036), but did not differ from one another in 239	
this regard (Z(2) = -0.445, p = 0.673). 240	
 241	
 242	
Discussion 243	
The impact of gray matter pathology, in particular that of gray matter lesions, on 244	
cognitive and physical functioning in MS patients has been discussed for many years. 245	
Here we highlight the clinical relevance of DIR-hyperintense cortical lesions in 246	
patients with RRMS. The most intriguing finding of the present study was that 247	
patients with - compared to those without visible cortical lesions - differed from each 248	
other in global cortical thickness and mnestic functions, whereas no differences 249	
between these two patient groups were observed regarding EDSS, age, age at 250	
diagnosis, disease duration, or non-mnestic cognitive functions. Moreover, patients 251	
without cortical lesions showed normal cortical thickness and mnestic functions, 252	
when compared with a group of healthy controls. 253	
That a reduction of cortical thickness can occur in MS [36] - and that this thinning is 254	
related to global [e.g. 26] and even specific cognitive impairment [38,39] - has been 255	
found in previous studies. Similar to a recent finding [40], we show an association 256	
between MS-related cortical thinning and the presence of cortical MS lesions. It is 257	
known that gray matter pathology involves both inflammatory and degenerative 258	
mechanisms, but the relationship between the two remains unclear [6]. Gray matter 259	
atrophy might be the final step of several pathological processes, which could include 260	
cortical demyelination but also retrograde degeneration secondary to white matter 261	
lesions and, perhaps, primary neurodegeneration [41]. 262	
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We detected DIR-hyperintense cortical lesions in 76% of our RRMS patients, 263	
supporting the notion of a high prevalence of these lesions [42]. In further agreement 264	
with previous findings [43], we observed an uneven spatial distribution of cortical 265	
lesions over the cerebral cortex, with a prominent accumulation in memory-relevant 266	
mesiotemporal regions, particularly in the bilateral parahippocampal gyrus. While the 267	
importance of the hippocampus for memory function is known since the classical 268	
description of the patient H.M. in 1957 [44], parahippocampal involvement in 269	
memory functions was recognized only two decades ago [45]. Squire and Zola-270	
Morgen identified the anatomical components of what is termed the medial temporal 271	
memory system [46]. By now it is well known that bilateral damage to the medial 272	
temporal lobe causes severe learning and memory impairments. This relationship has 273	
also been shown in MS patients. Learning and memory is the most frequently 274	
disrupted cognitive domain in MS, reported in 40-60 % of patients [47]. Moreover, 275	
Coebergh et al. [37] described a patient with acute memory impairment, associated 276	
with hippocampal and cortical lesions. Cortical lesions were also associated with 277	
cognitive decline in a group of 13 MS patients [38]. In this study, a significant 278	
correlation between hippocampal lesion load and visuospatial memory was observed. 279	
Based on the present and previous findings, we thus conclude that mesiotemporal 280	
cortical lesions are highly prevalent in RRMS patients and play a crucial role in the 281	
development of mnestic dysfunction. 282	
The association we found between memory impairment and both cortical thinning as 283	
well as cortical lesions seems particularly intriguing: One might speculate that 284	
mnestic dysfunction in MS patients could indicate cortical involvement of the MS 285	
pathology in general. Related to this assumption, a rarely occurring variant of so-286	
called 'cortical MS' has been described in previous studies [39, 40]. The condition was 287	
predominantly characterized by the presence of neurobehavioral symptoms (e.g. 288	
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depression, apathy) and neuropsychological deficits (e.g. agraphia, anomia) 289	
suggesting cortical dysfunction. However, detailed and explicit imaging data for 290	
detecting cortical involvement (e.g. DIR) is missing in these studies. By approaching 291	
from the imaging side, our patient group with cortical involvement may reflect a 292	
different and somehow incomplete variant of cortical MS, as they showed distinct 293	
mnestic deficits in association with cortical involvement, but no other cortical 294	
symptoms such for example depression. Moreover, we found no patient with cortical 295	
lesions in the absence of subcortical lesions. In all patients, including those of the CL 296	
group, the majority of MS lesions was located subcortically. Taking this into account, 297	
we here propose that our CL group may represent a 'cortically dominant' subtype of 298	
MS. In these patients, pathophysiological processes might be different from those of 299	
patients without cortical involvement.  300	
Beside the difference between the two patient groups in mnestic functions, both 301	
patient group showed executive deficits compared to the healthy control group. This 302	
finding is in line with previous studies that have shown significant executive 303	
dysfunction in MS patients [12,13]. 304	
Much research and clinical development in MS has focused on the inflammatory 305	
mechanisms of the disease. Meanwhile, multiple disease-modifying drugs (DMD) are 306	
available that target the inflammatory pathology of MS, in particular the development 307	
of new white matter lesions [48]. A recent study demonstrated that DMD - in 308	
particular IFN β-1a and glatiramer acetate - can reduce the accumulation of cortical 309	
lesions too [49]. In addition, Filippi and colleagues [50] showed that the presence of 310	
at least one cortical lesion is associated with a high risk of conversion from clinically 311	
isolated syndrome (CIS) to definite MS within a short period. Together with our 312	
results, these findings highlight the relevance of cortical lesions as a “target” in the 313	
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development of new DMD, and to include cortical lesions as a primary outcome 314	
variable in disease and treatment monitoring.   315	
This study is not without limitations. As already mentioned earlier, DIR represents 316	
only a limited snapshot of the real cortical pathology that is present in MS patients. 317	
The combination of DIR and a T1-weighted phase-sensitive inversion recovery 318	
(PSIR) sequence would substantially improve the sensitivity of detecting lesions 319	
present in the cortex of MS patients [51]. Moreover, the present analyses are limited 320	
due to the low MRI field (1.5T) applied. It has been shown that high field (3T) and 321	
ultra-high field (7T) MRI systems deliver a higher detection rate of cortical lesions in 322	
vivo [52]. Finally, a further limitation of the present study is the relatively small and 323	
unbalanced sample size.   324	
 325	
Conclusion 326	
In conclusion, the occurrence of cortical lesions in MS is clinically relevant insofar as 327	
it is associated with neurodegenerative cortical thinning and mnestic dysfunction. 328	
Although with today’s imaging techniques, it is only possible to visualize the 'tip of 329	
the iceberg' of cortical MS lesions [7,53], further progress in detection algorithms can 330	
be expected and will likely improve our understanding of MS pathology, symptoms, 331	
and treatment.  332	
 333	
Additional Files: 334	
- Additional File 1: additional_file_1.csv; Title/Description: Neuropsychological 335	
tests summarized in the three cognitive indices 336	
- Additional File 2: additional_file_2.csv; Title/Description: Detailed analyses of 337	
attentional, mnestic and executive functions (z-scores). 338	
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Table 1: Demographic and disease characteristics of multiple sclerosis patients and 534	
healthy controls  535	
 nCL group 
(n = 10), 
Mean (SD) 
CL group 
(n = 32), 
Mean (SD) 
Controls 
(n = 43), 
Mean (SD) 
Test p-value 
Age, years  32.6 (9.98) 38.22 (7.2) 36.1 (8.29) One-way ANOVA 0.155 
Education, years 15.5 (3.1) 14.45 (3.2) 14.58 (2.4) KW 0.408 
Cognitive reserve1  30.0 (3.1) 30.94 (3.4) 30.70 (2.3) KW 0.689 
EDSS 2.0 (1.8) 2.8 (1.8) - MW-U 0.174 
Age at diagnosis, years 26.7 (9.7) 30.65 (7.6) - t-test 0.185 
Disease duration, years 65.5 (59.6) 85.31 (68.9) - MW-U 0.570 
 536	
Abbreviations: nCL = patients without cortical lesions; CL = patients with cortical 537	
lesions; one-way ANOVA = one-way analysis of variance; EDSS = Expanded 538	
Disability Status Scale; KW = Kruskal-Wallis; MW-U = Mann-Whitney U 539	
1 Cognitive reserve was examined with passive vocabulary knowledge (multiple 540	
choice word test) 541	
	542	
 543	
 544	
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Figure legends 
Fig. 1: Spatial distribution of cortex-involving lesions in the CL patient group 
Overlap plot based on all normalized cortex-involving lesions found in all CL 
patients. Lesion frequency across the sample is displayed for every depicted voxel. 
The bar indicates the number of patients showing damage to a particular voxel. A) 
Axial and coronal views of lesion frequency. B) and C) Highest lesion overlap was 
found in the bilateral parahippocampal gyrus (MNI coordinates in B). Image 
orientation follows the radiological convention (right on left side).  
 
Fig. 2: Atrophy measurements 
Bars depict mean z-scores (and standard errors) of patients with (CL) and without 
cortex-involving (nCL) lesions as well as of healthy controls (HC). Note that the two 
patient groups differed only in global cortical thickness.  
 
Fig. 3: Indices of cognitive performance 
Bars show mean z-scores (and standard errors) of patients with (CL) and without 
cortex-involving (nCL) lesions as well as of healthy controls (HC). Note that the two 
patient groups differed only in mnestic functioning.  
	
	
